Literature DB >> 12498714

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.

Susan E Moody1, Christopher J Sarkisian, Kristina T Hahn, Edward J Gunther, Steven Pickup, Katherine D Dugan, Nathalie Innocent, Robert D Cardiff, Mitchell D Schnall, Lewis A Chodosh.   

Abstract

To determine the impact of tumor progression on the reversibility of Neu-induced tumorigenesis, we have used the tetracycline regulatory system to conditionally express activated Neu in the mammary epithelium of transgenic mice. When induced with doxycycline, bitransgenic MMTV-rtTA/TetO-NeuNT mice develop multiple invasive mammary carcinomas, essentially all of which regress to a clinically undetectable state following transgene deinduction. This demonstrates that Neu-initiated tumorigenesis is reversible. Strikingly, extensive lung metastases arising from Neu-induced mammary tumors also rapidly and fully regress following the abrogation of Neu expression. However, despite the near universal dependence of both primary tumors and metastases on Neu transgene expression, most animals bearing fully regressed Neu-induced tumors ultimately develop recurrent tumors that have progressed to a Neu-independent state.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498714     DOI: 10.1016/s1535-6108(02)00212-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  149 in total

Review 1.  Modeling metastasis in the mouse.

Authors:  Paula D Bos; Don X Nguyen; Joan Massagué
Journal:  Curr Opin Pharmacol       Date:  2010-07-01       Impact factor: 5.547

2.  The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells.

Authors:  B W Booth; C A Boulanger; L H Anderson; G H Smith
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

Review 3.  Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.

Authors:  Duane H Hamilton; Mary T Litzinger; Romaine I Fernando; Bruce Huang; Claudia Palena
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

4.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

Review 5.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

6.  Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.

Authors:  Pei Zhu; Meghan Davis; Amanda J Blackwelder; Nora Bachman; Bolin Liu; Susan Edgerton; Leonard L Williams; Ann D Thor; Xiaohe Yang
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-09

Review 7.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 8.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors:  Natalia V Sergina; Mark M Moasser
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

Review 9.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

10.  Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.

Authors:  Nathaniel W Mabe; Douglas B Fox; Ryan Lupo; Amy E Decker; Stephanie N Phelps; J Will Thompson; James V Alvarez
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.